|
Notification regarding unquoted securities - CUV
|
30 June 2023 at 12:20pm
|
|
Two Grounds of Appeal Upheld by NICE Panel
|
30 June 2023 at 9:40am
|
|
Notification of cessation of securities - CUV
|
29 June 2023 at 12:10pm
|
|
Presentation - Melbourne Twilight Briefing
|
29 June 2023 at 9:25am
|
|
Change of Director's Interest Notice
|
28 June 2023 at 10:20am
|
|
CLINUVEL Newsletter III - June 2023
|
26 June 2023 at 9:10am
|
|
Strategic Update VI
|
1 June 2023 at 9:55am
|
|
PRENUMBRA administered to moderate & severe stroke patients
|
9 May 2023 at 9:45am
|
|
Expansion of global porphyria programs
|
1 May 2023 at 9:30am
|
|
CLINUVEL Newsletter II - April 2023
|
5 April 2023 at 9:30am
|
|
Investor Presentation - NYC Nasdaq Event
|
30 March 2023 at 9:40am
|
|
Technical Note - CUV803 Study and AIS
|
20 March 2023 at 12:20pm
|
|
First stroke patient treated with PRENUMBRA Instant
|
20 March 2023 at 9:25am
|
|
DNA Repair data presented at AAD Meeting
|
17 March 2023 at 9:40am
|
|
Statement on Silicon Valley Bank
|
13 March 2023 at 9:25am
|
|
Proposed issue of securities - CUV
|
10 March 2023 at 3:10pm
|
|
Commercial Update SCENESSE
|
9 March 2023 at 11:05am
|
|
Relief from Quarterly Reporting
|
2 March 2023 at 12:30pm
|
|
CLINUVEL launches first dermatocosmetic product
|
1 March 2023 at 10:10am
|
|
Proposed issue of securities - CUV
|
28 February 2023 at 10:25am
|
|
Global SCENESSE demand drives increased revenues, earnings
|
24 February 2023 at 10:05am
|
|
CUV Appendix 4D Half Year Report
|
24 February 2023 at 10:05am
|
|
PRENUMBRA formulation completed for clinical trial use
|
15 February 2023 at 9:55am
|
|
Chair's Letter
|
9 February 2023 at 11:10am
|
|
Technical note - CUV151 results
|
2 February 2023 at 11:00am
|
|
Afamelanotide reduces UV skin damage in a healthy population
|
2 February 2023 at 11:00am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 January 2023 at 9:55am
|
|
NEURACTHEL manufacturing processes advance
|
23 January 2023 at 11:20am
|
|
Technical Note - Xeroderma Pigmentosum
|
16 January 2023 at 10:20am
|
|
afamelanotide Reduces DNA Photodamage in XP
|
16 January 2023 at 10:20am
|
|
CLINUVEL Newsletter I - January 2023
|
10 January 2023 at 11:25am
|
|
CLINUVEL Newsletter VI - December 2022
|
23 December 2022 at 11:50am
|
|
Notification of cessation of securities - CUV
|
21 December 2022 at 4:05pm
|
|
Presentation - Jefferies London Healthcare Conference
|
17 November 2022 at 9:20am
|
|
CLINUVEL Newsletter V - November 2022
|
9 November 2022 at 10:00am
|
|
Change of Director's Interest Notice
|
7 November 2022 at 11:40am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report Re-issued
|
31 October 2022 at 10:30am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 October 2022 at 9:30am
|
|
Results of Meeting
|
26 October 2022 at 12:45pm
|
|
Chair Address
|
26 October 2022 at 10:30am
|
|
Melbourne Investor Briefing Presentation
|
21 October 2022 at 9:35am
|
|
First vitiligo patient enrolled in monotherapy study
|
20 October 2022 at 10:15am
|
|
Investor Presentation - Sydney
|
14 October 2022 at 9:50am
|
|
Notice of Annual General Meeting/Proxy Form
|
23 September 2022 at 9:40am
|
|
Strategic Update V
|
19 September 2022 at 9:45am
|
|
Presentation - HC Wainright Global Investment Conference
|
13 September 2022 at 10:10am
|
|
Annual General Meeting Date
|
8 September 2022 at 12:05pm
|
|
CLINUVEL submits label expansion for adolescent EPP patients
|
5 September 2022 at 9:40am
|
|
S&P DJI Announces September 2022 Quarterly Rebalance
|
2 September 2022 at 5:30pm
|
|
CLINUVEL Investor Webinar Financial Results 2022
|
31 August 2022 at 10:00am
|
